|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
JP2003525201A
(ja)
*
|
1998-08-20 |
2003-08-26 |
スミスクライン・ビーチャム・コーポレイション |
新規な置換トリアゾール化合物
|
|
WO2000025791A1
(en)
|
1998-11-04 |
2000-05-11 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
PL215901B1
(pl)
|
1999-04-15 |
2014-02-28 |
Bristol Myers Squibb Co |
Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
EP1233951B1
(en)
|
1999-11-23 |
2005-06-01 |
SmithKline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
|
ATE305787T1
(de)
|
1999-11-23 |
2005-10-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
|
|
AU1781601A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
AU2001237401B2
(en)
*
|
2000-03-01 |
2006-11-09 |
Janssen Pharmaceutica N.V. |
2,4-disubstituted thiazolyl derivatives
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
ATE521353T1
(de)
*
|
2000-10-23 |
2011-09-15 |
Glaxosmithkline Llc |
Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
|
|
CA2433018A1
(en)
|
2000-12-21 |
2002-06-27 |
Joel C. Barrish |
Thiazolyl inhibitors of tec family tyrosine kinases
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
ATE415162T1
(de)
|
2001-06-11 |
2008-12-15 |
Vertex Pharma |
Isochinolin-inhibitoren von p38
|
|
HN2002000156A
(es)
|
2001-07-06 |
2003-11-27 |
Inc Agouron Pharmaceuticals |
Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
|
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
DK1466912T3
(da)
|
2002-01-18 |
2013-07-01 |
Astellas Pharma Inc |
2-acylaminothiazolderivat eller salt deraf
|
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
|
MXPA04007830A
(es)
|
2002-02-11 |
2005-07-01 |
Bayer Pharmaceuticals Corp |
Arilureas como inhibidores de cinasa.
|
|
EP2258687B1
(en)
|
2002-02-12 |
2012-12-26 |
Glaxosmithkline LLC |
Nicotinamide derivates useful as P38 inhibitors
|
|
KR101025675B1
(ko)
*
|
2002-04-23 |
2011-03-30 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
|
|
AU2003245555A1
(en)
*
|
2002-06-17 |
2003-12-31 |
The Pennsylvania State Research Foundation |
Sphingosine kinase inhibitors
|
|
DE60310730T2
(de)
|
2002-07-09 |
2007-05-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
CN101723891A
(zh)
|
2003-02-10 |
2010-06-09 |
沃泰克斯药物股份有限公司 |
通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
|
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
WO2004113274A2
(en)
|
2003-05-20 |
2004-12-29 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
|
US7652044B2
(en)
*
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
EA010485B1
(ru)
|
2003-07-23 |
2008-10-30 |
Байер Фамэсьютиклс Копэрейшн |
Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
|
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
US7244441B2
(en)
*
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
|
WO2005032551A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
EP1865959A2
(en)
*
|
2005-03-25 |
2007-12-19 |
Glaxo Group Limited |
Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
|
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
NZ563866A
(en)
*
|
2005-05-09 |
2011-03-31 |
Achillion Pharmaceuticals Inc |
Thiazole compounds and methods of use
|
|
WO2006127678A2
(en)
*
|
2005-05-23 |
2006-11-30 |
Smithkline Beecham Corporation |
Inhibition of p38 mark for treatment of obesity
|
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
IL169855A
(en)
*
|
2005-07-25 |
2014-05-28 |
Elta Systems Ltd |
A system and method for locating a receiver location
|
|
AR058439A1
(es)
|
2005-07-26 |
2008-02-06 |
Portela & Ca Sa |
Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
|
|
WO2007103550A2
(en)
*
|
2006-03-08 |
2007-09-13 |
Achillion Pharmaceuticals, Inc. |
Substituted aminothiazole derivatives with anti-hcv activity
|
|
EP1845097A1
(en)
*
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
EP2452674B1
(en)
*
|
2006-08-08 |
2014-03-26 |
Akarx, Inc. |
Compositions and methods for increasing blood platelet levels in humans
|
|
EP2481410B1
(en)
|
2007-01-31 |
2016-07-13 |
BIAL - Portela & Ca., S.A. |
Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
|
|
CA2681420A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Cadila Pharmaceuticals Limited |
P38 inhibitors
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
US8183263B2
(en)
*
|
2007-05-22 |
2012-05-22 |
Achillion Pharmaceuticals, Inc. |
Heteroaryl substituted thiazoles
|
|
WO2009108077A2
(en)
*
|
2008-02-28 |
2009-09-03 |
Bial - Portela & Ca., S.A. |
Pharmaceutical composition for poorly soluble drugs
|
|
KR20110002462A
(ko)
|
2008-03-17 |
2011-01-07 |
바이알 - 포르텔라 앤드 씨에이 에스에이 |
5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
|
|
US8106209B2
(en)
*
|
2008-06-06 |
2012-01-31 |
Achillion Pharmaceuticals, Inc. |
Substituted aminothiazole prodrugs of compounds with anti-HCV activity
|
|
BRPI0922572A2
(pt)
|
2008-12-17 |
2019-09-24 |
Scripps Research Inst |
método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
|
|
EP2396302A2
(en)
*
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
|
RU2550133C2
(ru)
*
|
2009-04-01 |
2015-05-10 |
БИАЛ-ПОРТЕЛА энд КА., С.А. |
Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
|
|
AU2010231961B2
(en)
*
|
2009-04-01 |
2015-05-21 |
Bial - Portela & Ca., S.A. |
Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
|
|
EP2464352A1
(en)
*
|
2009-08-14 |
2012-06-20 |
Eisai Inc. |
Use of e5501 for stimulating platelet production
|
|
US9359300B2
(en)
|
2010-12-06 |
2016-06-07 |
Confluence Life Sciences, Inc. |
Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
|
|
US8507499B2
(en)
|
2010-12-06 |
2013-08-13 |
Confluence Life Sciences, Inc. |
Substituted indole/indazole-pyrimidinyl compounds
|
|
WO2012078673A1
(en)
|
2010-12-06 |
2012-06-14 |
Confluence Life Sciences, Inc. |
Substituted pyridine urea compounds
|
|
US20120142709A1
(en)
|
2010-12-06 |
2012-06-07 |
Selness Shaun R |
Substituted pyridinone-pyridinyl compounds
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
US9056110B2
(en)
|
2011-12-06 |
2015-06-16 |
Confluence Life Sciences, Inc. |
Substituted pyrimidinone-phenyl-pyrimidinyl compounds
|
|
WO2013089573A1
(en)
|
2011-12-13 |
2013-06-20 |
BIAL - PORTELA & Cª., S.A. |
Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
|
|
EP2843049B1
(en)
*
|
2012-04-27 |
2018-04-11 |
Keio University |
Neuronal differentiation promoter
|
|
SMT202100117T1
(it)
|
2013-06-07 |
2021-05-07 |
Aclaris Therapeutics Inc |
Composti piridinone-piridinile sostituiti con metil/fluoro-piridinil-metossi e composti piridinone-piridinile sostituiti con fluoro-pirimidinil-metossi
|
|
JP2018500300A
(ja)
|
2014-11-28 |
2018-01-11 |
ノヴィファーマ，エス．アー． |
パーキンソン病を遅延させるための医薬
|
|
WO2017075274A1
(en)
|
2015-10-27 |
2017-05-04 |
Children's Hospital Medical Center |
Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
|
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
WO2019071147A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
|
|
EP3773579A4
(en)
|
2018-03-26 |
2022-03-09 |
Clear Creek Bio, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
|
|
RU2709496C1
(ru)
*
|
2019-08-01 |
2019-12-18 |
Марат Феликсович Фазылов |
Способ получения аватромбопага
|
|
US20210300873A1
(en)
|
2020-03-20 |
2021-09-30 |
Clear Creek Bio, Inc. |
Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
|
|
BR112022019349A2
(pt)
|
2020-03-27 |
2022-11-16 |
Aclaris Therapeutics Inc |
Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto
|
|
WO2022195579A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
|